Amicus Therapeutics, Inc.
US ˙ NasdaqGM ˙ US03152W1099
DIESES SYMBOL IST NICHT MEHR AKTIV

SecurityFOLD / Amicus Therapeutics, Inc.
InstitutionEngineers Gate Manager LP
Latest Disclosed Ownership192,500 shares
Latest Disclosed Value $ 2,783,550
Engineers Gate Manager LP reports 144.73% increase in ownership of FOLD / Amicus Therapeutics, Inc.

On May 15, 2026 - Engineers Gate Manager LP filed a 13F-HR form disclosing ownership of 192,500 shares of Amicus Therapeutics, Inc. (US:FOLD) valued at $2,783,550 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 78,659 shares of Amicus Therapeutics, Inc.. This represents a change in shares of 144.73% during the quarter. The current value of the position is $2,789,325 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F AMICUS THERAPEUTIC COM 03152W109 192,500 113,841 144.73 2,784 148.48 0.0348
2026-02-17 2025-12-31 13F AMICUS THERAPEUTICS COM 03152W109 78,659 -153,493 -66.12 1,120 -38.76 0.0133
2025-11-14 2025-09-30 13F AMICUS THERAPEUTICS COM 03152W109 232,152 -409,237 -63.80 1,829 -50.23 0.0209
2025-08-14 2025-06-30 13F AMICUS THERAPEUTICS COM 03152W109 641,389 479,038 295.06 3,675 177.57 0.0457
2025-05-15 2025-03-31 13F AMICUS THERAPEUTICS COM 03152W109 162,351 57,943 55.50 1,325 34.69 0.0223
2025-02-14 2024-12-31 13F AMICUS THERAPEUTICS COM 03152W109 104,408 -46,314 -30.73 984 -38.91 0.0171
2024-11-14 2024-09-30 13F AMICUS THERAPEUTICS COM 03152W109 150,722 111,985 289.09 1,610 319.01 0.0314
2024-08-14 2024-06-30 13F AMICUS THERAPEUTICS COM 03152W109 38,737 -54,797 -58.59 384 -65.12 0.0087
2024-05-15 2024-03-31 13F AMICUS THERAPEUTICS COM 03152W109 93,534 66,252 242.84 1,102 184.50 0.0290
2024-02-14 2023-12-31 13F AMICUS THERAPEUTICS COM 03152W109 27,282 6,765 32.97 387 55.42 0.0111
2023-11-14 2023-09-30 13F AMICUS THERAPEUTICS COM 03152W109 20,517 -54,621 -72.69 249 -73.59 0.0092
2023-08-14 2023-06-30 13F AMICUS THERAPEUTICS COM 03152W109 75,138 52,966 238.89 944 284.90 0.0357
2023-05-15 2023-03-31 13F AMICUS THERAPEUTICS COM 03152W109 22,172 4,199 23.36 246 11.87 0.0103
2023-02-14 2022-12-31 13F AMICUS THERAPEUTICS COM 03152W109 17,973 7,854 77.62 219 106.60 0.0132
2022-11-14 2022-09-30 13F AMICUS THERAPEUTICS COM 03152W109 10,119 10,119 106 0.0066
2022-08-15 2022-06-30 13F AMICUS THERAPEUTICS COM 03152W109 0 -20,371 -100.00 0 -100.00
2022-05-16 2022-03-31 13F AMICUS THERAPEUTICS COM 03152W109 20,371 20,371 193 0.0076
2022-02-14 2021-12-31 13F AMICUS THERAPEUTICS COM 03152W109 0 -23,466 -100.00 0 -100.00
2021-11-15 2021-09-30 13F AMICUS THERAPEUTICS COM 03152W109 23,466 -82,079 -77.77 224 -77.97 0.0128
2021-08-16 2021-06-30 13F AMICUS THERAPEUTICS COM 03152W109 105,545 84,545 402.60 1,017 391.30 0.0654
2021-05-17 2021-03-31 13F AMICUS THERAPEUTICS COM 03152W109 21,000 454 2.21 207 -56.33 0.0103
2021-02-16 2020-12-31 13F AMICUS THERAPEUTICS COM 03152W109 20,546 -48,290 -70.15 474 -51.23 0.0206
2020-11-16 2020-09-30 13F AMICUS THERAPEUTICS COM 03152W109 68,836 55,178 404.00 972 371.84 0.0456
2020-08-17 2020-06-30 13F AMICUS THERAPEUTICS COM 03152W109 13,658 13,658 206 0.0105
2020-05-15 2020-03-31 13F AMICUS THERAPEUTICS COM 03152W109 0 -98,197 -100.00 0 -100.00
2020-02-14 2019-12-31 13F AMICUS THERAPEUTICS COM 03152W109 98,197 86,197 718.31 956 895.83 0.0420
2019-11-14 2019-09-30 13F AMICUS THERAPEUTICS COM 03152W109 12,000 12,000 96 0.0049
2019-08-14 2019-06-30 13F AMICUS THERAPEUTICS COM 03152W109 0 -22,900 -100.00 0 -100.00
2019-05-15 2019-03-31 13F AMICUS THERAPEUTICS COM 03152W109 22,900 22,900 311 0.0188
2018-02-01 2017-12-31 13F AMICUS THERAPEUTICS COM 03152W109 0 -10,300 -100.00 0 -100.00
2017-11-13 2017-09-30 13F AMICUS THERAPEUTICS COM 03152W109 10,300 10,300 155 0.0130
2016-05-09 2016-03-31 13F AMICUS THERAPEUTICS COM 03152W109 0 -17,671 -100.00 0 -100.00
2016-02-05 2015-12-31 13F AMICUS THERAPEUTICS COM 03152W109 17,671 17,671 171 0.0115
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.